Evidence map›Paper›PMID 31003599›Full record

ArticleJournal of medical case reports2019

Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report.

Tomohisa Kunii, Toshie Iijima, Teruo Jojima, Masanori Shimizu, Masato Kase, Shintaro Sakurai, Takahiko Kogai, Isao Usui, Yoshimasa Aso

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tomohisa KuniiDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
Toshie IijimaDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, 321-0293, Japan. toshie@dokkyomed.ac.jp.ORCID http://orcid.org/0000-0002-4613-3744
Teruo JojimaDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
Masanori ShimizuDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
Masato KaseDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
Shintaro SakuraiDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
Takahiko KogaiDepartment of Infection Control and Clinical Laboratory Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan.
Isao UsuiDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
Yoshimasa AsoDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
Dokkyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdefovir dipivoxil is a nucleotide analogue that is approved for treatment of chronic hepatitis B. Adefovir dipivoxil is associated with proximal tubular dysfunction, resulting in Fanconi syndrome, which can cause secondary hypophosphatemic osteomalacia. We describe a case of a patient with hypophosphatemic osteomalacia secondary to Fanconi syndrome induced by adefovir dipivoxil concomitantly with osteoporosis in whom clinical symptoms were improved by adding denosumab (a human monoclonal antibody targeting the receptor activator of nuclear factor-κB ligand) to preceding administration of vitamin D CASE PRESENTATION: A 60-year-old Japanese man had been receiving low-dose adefovir dipivoxil (10 mg/day) to treat chronic hepatitis B for approximately 5 years. He presented to an orthopedic surgeon with severe pain of the right hip and no trauma history, and fracture of the neck of the right femur was identified. In addition,

conclusionsAlthough denosumab is not generally an appropriate treatment for acquired Fanconi syndrome, it may be useful for patients who have hypophosphatemic osteomalacia due to adefovir dipivoxil-induced Fanconi syndrome associated with excessive bone resorption. However, clinicians should keep in mind that if denosumab is administered to patients with hypophosphatemic osteomalacia accompanied by excessive bone resorption, adequate vitamin D and/or phosphate supplementation should be done before administration of denosumab.

Indexed as

HypophosphatemiaOsteomalaciaAdenineAdultAntiviral AgentsBone Density Conservation AgentsDenosumabFanconi SyndromeHepatitis BHumansMaleMiddle AgedOrganophosphonatesTomography, Emission-ComputedTreatment Outcomeadefovir dipivoxilAdenineAntiviral AgentsBone Density Conservation AgentsDenosumabOrganophosphonatesAdefovir dipivoxilChronic hepatitis BDenosumabFanconi syndromeOsteomalaciaOsteoporosis

Identifiers

PMID31003599
PMCPMC6475105
OpenAlexW2939361435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.